文献速递艾滋病与性传播感染

巨细胞病毒免疫球蛋白G(IgG)滴度与人免疫缺陷病毒(HIV)感染者的冠状动脉疾病

Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV).
PubMed 文献 · Clin Infect Dis · 2023-01-01

在REPRIEVE试验美国参与者子集中,672例接受稳定抗逆转录病毒治疗、ASCVD风险低至中度的HIV感染者入组时接受冠状动脉CT血管造影。巨细胞病毒IgG滴度与部分炎症生物标志物单变量相关,但控制HIV特异性因素后无关联;与斑块存在、CAC评分>0、易损斑块或Leaman评分>5均无关联。

要点

  • HIV感染者中巨细胞病毒IgG滴度较高与年龄较大及当前和最低CD4+ T细胞计数较低相关。
  • 巨细胞病毒IgG滴度与sCD163、MCP-1、IL-6、hsCRP单变量相关,控制HIV特异性因素后无关联。
  • 巨细胞病毒IgG滴度与斑块存在、CAC评分>0、易损斑块或Leaman评分>5无关联。

核心结论

  • 在入组时接受抗逆转录病毒治疗的HIV感染者中,巨细胞病毒IgG滴度与冠状动脉疾病指标之间未见有意义的关联。
  • REPRIEVE的纵向评估将确定巨细胞病毒IgG滴度与斑块进展和心血管事件的关系。

研究设计与样本

  • REPRIEVE(预防HIV血管事件随机试验)纳入40-75岁、接受稳定抗逆转录病毒治疗、ASCVD风险低至中度的HIV感染者。
  • 在美国REPRIEVE参与者子集中,通过冠状动脉CT血管造影评估冠状动脉斑块,分析入组时巨细胞病毒IgG滴度与免疫激活水平、炎症生物标志物及冠状动脉斑块表型的关系。
  • 共672例参与者,平均年龄51岁,83%为男性,中位ASCVD风险评分4.5%,66%当前CD4+ T细胞计数≥500 cells/mm3。

主要发现

  • 较高的巨细胞病毒IgG四分位组与年龄较大及当前和最低CD4+ T细胞计数较低相关。
  • 巨细胞病毒IgG滴度在单变量分析中与特定炎症生物标志物(sCD163、MCP-1、白细胞介素[IL]-6、hsCRP)相关,但控制HIV特异性因素后无关联。
  • 巨细胞病毒IgG滴度与冠状动脉疾病指标无关联,包括斑块存在、冠状动脉钙化(CAC)评分>0、易损斑块存在或Leaman评分>5。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cytomegalovirus (CMV) infection is thought to result in increased immune activation in people with human immunodeficiency virus (HIV, PWH). Although some data have linked asymptomatic CMV infection to cardiovascular disease among PWH, it remains unknown whether CMV is associated with increased or high-risk coronary plaque. METHODS: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) enrolled PWH aged 40-75 years on stable antiretroviral therapy (ART) with low-to-moderate atherosclerotic cardiovascular disease (ASCVD) risk. Among a subset of US REPRIEVE participants, coronary plaque was assessed by coronary computed tomography angiography. Here, we assessed the relationship between CMV immunoglobulin G (IgG) titer and (1) levels of immune activation, (2) inflammatory biomarkers, and (3) coronary plaque phenotypes at study entry. RESULTS: Of 672 participants, mean age was 51 years, 83% were men, median ASCVD risk score was 4.5%, and 66% had current CD4+ T-cell count ≥500 cells/mm3. Higher CMV IgG quartile group was associated with older age and lower current and nadir CD4+ T-cell counts. CMV IgG titer was associated with specific inflammatory biomarkers (sCD163, MCP-1, interleukin [IL]-6, hsCRP) in univariate analysis, but not after controlling for HIV-specific factors. In contrast, CMV IgG titer was not associated with coronary artery disease indexes, including presence of plaque, coronary artery calcium (CAC) score >0, vulnerable plaque presence, or Leaman score >5. CONCLUSIONS: No meaningful association was seen between CMV IgG titer and coronary artery disease indexes among ART-treated PWH at study enrollment. Longitudinal assessments in REPRIEVE will determine the relationship of CMV IgG titer to plaque progression and cardiovascular events. CLINICAL TRIALS REGISTRATION: NCT02344290.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Schnittman SR, Lu MT, Mayrhofer T, et al. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2023. PMID: 35975297. doi:10.1093/cid/ciac662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。